膀胱过度活动症治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00004082
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 209
Buy Now

膀胱过度活动症治疗市场预计将从2021年的42.9593亿美元增长到2028年的53.3392亿美元;预计 2022 年至 2028 年复合年增长率为 3.1%。

膀胱过度活动症 (OAB) 是指频繁、突然的排尿冲动,可能难以控制。 OAB 可由腹部创伤、感染、神经损伤和某些药物引起。 OAB 在 65 岁及以上的人群中很常见。女性 45 岁后可能患有 OAB。治疗包括改变某些行为、药物和神经刺激。

膀胱过度活动症治疗市场分为药物治疗、疾病类型和地理位置。按地域划分,市场大致分为北美、欧洲、亚太地区、中东和中东地区。非洲、南美和非洲中美洲。膀胱过度活动症治疗市场报告提供了对市场的见解和深入分析,强调了市场趋势、市场动态以及全球领先市场参与者的竞争分析等参数。

战略见解

膀胱过度活动症治疗市场利润丰厚的地区

市场洞察

根据美国国家失禁协会的数据,2018年,全球约有2亿人受到尿失禁的影响。压力性尿失禁和急迫性尿失禁是影响女性的两种常见类型的尿失禁,其中后者也称为膀胱过度活动症。同样,美国内科医师学会和美国传染病学会的一组研究人员于 2020 年进行的一项研究表明,尿路感染 (UTI) 是美国每年约 600 万人就诊的原因。在加拿大,每年约有 500,000 人次前往医生办公室进行 UTI 咨询。尿路感染分别是该国门诊就诊和急诊就诊的第八和第五常见原因。因此,尿失禁患病率的增加和尿路感染发病率的增加正在推动膀胱过度活动症治疗市场的发展。

以下是新产品发布和批准的一些示例:

  • 2022 年 2 月,Alembic Pharmaceuticals 的富马酸非索罗定缓释片仿制药获得美国卫生监管机构的批准,用于治疗具有尿失禁、尿急和尿频症状的成人膀胱过度活动症。获得美国食品和药物管理局的批准美国食品药品监督管理局 (USFDA) 批准的富马酸非索罗定缓释片的简化新药申请 (ANDA) 规格为 4 毫克和 8 毫克。
  • 2022 年 4 月,Axonics, Inc. 成为全球医疗技术公司公司开发和商业化用于治疗膀胱和肠道功能障碍的新产品——宣布在美国全面推出 Axonics F15。新开发的长寿命、完全免充电的骶神经调节 (SNM) 系统于 3 月份获得 FDA 批准。 Axonics 免充电系统对于患有膀胱和肠道功能障碍的患者来说是一项值得欢迎的进步。
  • 2021 年 3 月,Astellas Pharma 的 Myrbetriq 用于治疗 3 岁儿科患者的神经源性逼尿肌过度活动症 (NDO)岁及以上(体重 35 公斤或以上)和 Myrbetriq 颗粒 - 用于治疗三岁及以上儿童患者的 NDO - 已获得美国食品和药物管理局 (FDA) 批准。

市场参与者的此类产品开发正在推动膀胱过度活动症治疗市场。

类型洞察

基于药物疗法,膀胱过度活动症治疗市场细分为米拉贝隆、肉毒杆菌、神经刺激、抗胆碱能药物和膀胱内滴注。米拉贝隆细分市场在 2021 年占据最大市场份额,预计在预测期内复合年增长率最高。米拉贝隆单独使用或与索利那新一起用于治疗成人膀胱过度活动症。它用于治疗三岁或以上儿童的神经源性逼尿肌过度活动(由大脑、脊髓或神经问题引起的膀胱控制病症)。米拉贝隆属于一类称为 β-3 肾上腺素能激动剂的药物。它可以放松膀胱肌肉,防止尿急、尿频或失控。米拉贝隆有缓释(长效)片剂和可口服的缓释混悬剂两种形式。2022 年 10 月,Zydus Pharmaceuticals Inc. 获得美国 FDA 批准上市米拉贝隆缓释片 USP 25毫克和50毫克。预计对这种疗法的需求不断增长将推动预测期内膀胱过度活动症治疗市场的增长。

膀胱过度活动症治疗市场(按类型) 2021年和2028年

服务洞察

根据药物治疗,膀胱过度活动症治疗市场分为米拉贝隆、肉毒杆菌、神经刺激、抗胆碱能药物和膀胱灌注。预计神经刺激领域在预测期内将达到市场上最高的复合年增长率。膀胱的神经控制很复杂,取决于不同的脊髓、中枢和周围神经及其多种反射途径。神经控制是在人体的不同部位进行的,因此针对不同的神经。其中一些目标神经直接参与下尿路感觉运动控制,例如骶神经或阴部神经,而其他神经则间接参与。电刺激用于激活这些神经来控制膀胱。

伙伴关系和协作是全球膀胱过度活动症治疗市场参与者高度采用的策略。下面列出了近期的一些关键市场动态:

  • 2021 年 4 月,美敦力公司 (Medtronic plc) 宣布获得美国食品和药物管理局 (FDA) 的批准继续进行研究性设备豁免 (IDE) 试验,以评估其内部开发的植入式胫骨神经调节 (TNM) 设备,该设备旨在缓解膀胱失禁症状。
  • 2020 年 7 月,Hisamitsu Pharmaceutical Co ., Inc. 宣布批准在泰国生产和销售 OABLOK PATCH。该产品是一种全身性透皮制剂,采用久光的透皮给药系统(TDDS)技术开发,用于治疗膀胱过度活动症的尿急、尿频等症状。
  • 2019年7月,梯瓦制药有限公司(Teva Pharmaceuticals Ltd.)推出琥珀酸索利那新片,一种毒蕈碱拮抗剂,用于治疗伴有尿失禁和尿频增加症状的膀胱过度活动症。

COVID-19 大流行已经为玩家带来了一些有利的情况在膀胱过度活动症治疗市场。美国是北美受影响最严重的国家。该感染严重影响了该国的老年人口,引起各种并发症并导致大量人口死亡。例如,截至 2022 年 5 月 16 日,美国报告了 84,230,829 例新冠病例,其中 1,026,670 人死亡。因此,需要进行膀胱过度活动症治疗和适当护理,以预防慢性感染病例和健康状况。

COVID-19 爆发后,OAB 的发病率有所增加。 根据美国泌尿外科协会的一项研究表明,感染 COVID-19 的患者出现新的膀胱过度活动症症状或出现膀胱过度活动症症状恶化的风险增加。此外,在感染两个月后进行的尿失禁问卷膀胱过度活动模块国际咨询 (ICIQ-OAB) 中,大约三分之一的 COVID-19 患者报告临床症状显着增加。在这三分之一的患者中,大约有五分之一的患者报告说他们的 OAB 症状是新出现的。 COVID-19 导致的 OAB 患病率增加,对大流行期间膀胱过度活动症治疗的需求产生了积极影响。

膀胱过度活动症治疗 –市场细分

根据药物治疗、疾病类型和地理位置对全球膀胱过度活动症治疗市场进行分析。根据药物治疗,膀胱过度活动症治疗市场分为米拉贝隆、肉毒杆菌、神经刺激、抗胆碱能药物和膀胱灌注。根据疾病类型,市场分为特发性膀胱过度活动症和神经源性膀胱。从地域上看,膀胱过度活动症治疗市场分为北美、欧洲、亚太地区、中东和欧洲。非洲、南美和非洲中美洲。

公司简介

  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc
  • AbbVie Inc
  • Teva Pharmaceuticals Industries Ltd
  • Endo Pharmaceuticals Inc
  • Hisamitsu Pharmaceutical Co. Inc
  • Medtronic Plc
  • Colorado Urology Associates, PLLC
  • >
  • Axonics Modulation Technologies, Inc
  • 辉瑞公司
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which segment by pharmacotherapy led the overactive bladder treatment market?

The mirabegron segment held the largest share of the market in 2021. However, neurostimulation is expected to grow at the highest CAGR during the forecast period.

Which region is projected to be the fastest-growing region in the global overactive bladder treatment market?

The Asia Pacific is expected to be the fastest-growing region in the overactive bladder treatment market over the forecast period due to the rising geriatric population, increasing urinary incontinence cases, and a surge in product launches.

What is the market CAGR value of the overactive bladder treatment market during the forecast period?

The CAGR value of the overactive bladder treatment market during the forecasted period of 2022-2028 is 3.1%.

What is the estimated overactive bladder treatment market size in 2021?

The overactive bladder treatment market is estimated to be valued at US$ 4,295.93 million in 2021.

What are the growth estimates for the overactive bladder treatment market till 2028?

The overactive bladder treatment market is expected to be valued at US$ 5,333.92 million in 2028.

Who are the major players in the overactive bladder treatment market across the globe?

The overactive bladder treatment market majorly consists of the players, such as Alembic Pharmaceuticals Limited, Astellas Pharma Inc; Pfizer Inc; AbbVie Inc; Teva Pharmaceutical Industries Ltd; Endo Pharmaceuticals Inc; Hisamitsu Pharmaceutical Co., Inc; Medtronic Plc; Colorado Urology Associates, PLLC; Axonics Modulation Technologies, Inc.

What are the driving factors for the global overactive bladder treatment market across the world?

The factors that are driving the growth of the overactive bladder treatment market are urinary tract infections (UTI) which lead to increased activity in the bladder wall muscles, causing symptoms like an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities may further damage the integrity of the urothelial barrier. The increasing prevalence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the overactive bladder treatment market growth.

What are overactive bladder treatments?

The sudden need to urinate causes a problem with bladder dysfunction. An overactive bladder may affect how often you pee and your urgency. Causes include abdominal trauma, infection, nerve damage, medications, and certain fluids. Treatment includes changing certain behaviors, medications, and nerve stimulation. Overactive bladder is common in people aged 65 and older. Women may have OAB at a younger age, usually around 45.

The List of Companies -Overactive Bladder Treatment Market

  1. Alembic Pharmaceuticals Limited
  2. Astellas Pharma Inc
  3. Pfizer Inc
  4. AbbVie Inc
  5. Teva Pharmaceutical Industries Ltd
  6. Endo Pharmaceuticals Inc.
  7. Hisamitsu Pharmaceutical Co.,Inc
  8. Medtronic Plc
  9. Colorado Urology Associates, PLLC
  10. Axonics Modulation Technologies, Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports